Analysis of the prospects for medical insurance inclusion of serputinib/serpatinib in 2025

Selpercatinib has been approved for marketing in China, but has not yet been included in the national medical insurance directory. Its market price is more than RMB 10,000 per box of 80mg*56 tablets. Due to its high price, medical insurance coverage has become an important factor in whether patients can take the drug for a long time. As a precise targeted drug for RET-driven tumors, seputinib has filled the gap in domestic RET targeted treatments. Therefore, its inclusion in medical insurance has strong clinical value and policy feasibility.

From experience,The efficacy and target clarity of RET targeted drugs make it easier to obtain reimbursement support under the trend of precision medicine. Domestic medical insurance policies have gradually tilted towards innovative targeted drugs in recent years, especially for irreplaceable high-value anti-cancer drugs, which are usually included in the catalog through negotiation or special medical insurance to reduce the financial burden on patients. Considering that the RET-positive patient group targeted by Seputinib is relatively limited, the high price of the drug may be a consideration in medical insurance negotiations, but its obvious clinical benefits and safety are important basis for promoting inclusion in medical insurance.

In addition, the domestic promotion ofRET testing will also affect the pace of medical insurance inclusion. If more hospitals have RET gene testing capabilities, patients can identify molecular targets, and medical insurance coverage will be more targeted and efficient. When evaluating inclusion, policymakers will take into account drug efficacy, patient group size, economic burden and clinical urgency, which provides positive conditions for the inclusion of seputinib in medical insurance.

In the future, with the accumulation of global and domestic data and the increase in patient demand for medication, there is a higher possibility that seputinib will be included in medical insurance. If included in medical insurance, the price is expected to drop, benefiting more patients with RET-positive tumors. At the same time, medical insurance coverage will also promote the popularization of related genetic testing, form a closed loop of precision medicine, and further improve treatment effects and patients' quality of life.

Reference:https://en.wikipedia.org/wiki/Selpercatinib